Acrivon Therapeutics, Inc. ACRV 深 滬
等待開盤 03-26 09:30:00 美东时间
1.52
-0.060
-3.80%
華盛通- 最 高1.67
- 今 開1.61
- 成交量 78.03万股
- 最 低 1.52
- 昨 收 1.58
- 總市值 4796.38万
- 52周最高 3.56
- 市盈率 靜 --
- 換手率 2.47%
- 52周最低 1.05
- 委 比 22.87%
- 總股本 3155.51万
- 歷史最高 25.47
- 量 比 1.48
- 振 幅 9.49%
- 歷史最低 1.05
- 每 手 1
- 風險率 0.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Acrivon Therapeutics Q4 net loss narrows as expenses fall
Acrivon Therapeutics Q4 net loss narrows as expenses fall Overview US biopharma firm's Q4 net loss narrowed from prior year as expenses declined Research and development and administrative costs fell, driven by fewer milestones and lower personnel costs Company expects cash and investments to fund o
03-19 19:28
Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.57) by 13.58 percent. This is a 18.33 percent increase over losses of $(0.60) per share
03-19 19:23
BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million
BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million Mar 19 (Reuters) - Acrivon Therapeutics, Inc Q4 operating expenses USD 20.116 million. Q4 basic EPS USD -0.49 Q4 net income USD -18.985 million
03-19 19:22
Acrivon Therapeutics To Reveal Pre-Clinical AP3 Data At The 2026 AACR Annual Meeting
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ACR-2316,
03-18 05:57
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
Acrivon Therapeutics announced three poster presentations at the AACR Annual Meeting 2026, highlighting promising results from their precision medicines. ACR-368, a CHK1/2 inhibitor, showed potent synergy with Topo1 inhibitors, commonly used in ADCs, overcoming resistance mechanisms. ACR-2316, a WEE1/PKMYT1 inhibitor, demonstrated complete tumor regression and durable immune protection when combined with anti-PD-L1 checkpoint inhibition in precli...
03-17 21:54
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
Acrivon Therapeutics has received CLIA certification for its internal laboratory in Watertown, Massachusetts, enabling patient testing and companion diagnostic development. The lab enhances the company's capabilities in precision medicine, biomarker discovery, and therapeutic development, while improving efficiency and reducing reliance on external partners. Acrivon is leveraging its proprietary Generative Phosphoproteomics AP3 platform to advanc...
02-18 13:00
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Acrivon Therapeutics will present interim clinical data for ACR-368, a precision medicine targeting endometrial cancer, at the ESGO 27th Annual Congress in Copenhagen. Dr. Panagiotis Konstantinopoulos, a global KOL, will highlight the data from the Phase 2b study, showcasing the drug's potential in a high unmet need population. The presentation is scheduled for Feb 27, 2026. Acrivon's proprietary Generative Phosphoproteomics AP3 platform drives i...
01-23 13:11
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Market-Moving News for January 8th
ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Accelerates ACRV: 38% | Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial Clinical
01-08 20:35
Acrivon Therapeutics to Release New Cancer Drug Data on Jan. 8
Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics
01-06 20:34
